Well, it is official. The inhaled insulin Exubera is being pulled from the market by Pfizer. An ADA article reports that Pfizer took a $2.8 Billion hit to end its involvement with the sale of the drug. Doctoral and patient support, as well as profits, has been too dismal to warrant any kind of extended sale of what was seen as a breakthrough in diabetes management by many. (READ MORE)







